More generally, we investigated the distribution of other clinical phenotypes (age, tumor size, vascular invasion, NPI, lymph node status, distant metastasis, overall survival, p53 mutation status and the immunohistochemical markers PGR, ERBB2, p53 and AR) in the 26-sample low-GII cluster relative to the rest of the cohort, as well as the differential distribution of the same clinical factors among the two groups when restricted to ER- samples only. Here, TP53 is linked to neoplasm.